Lacking internal research capabilities, Mirum's core business model is to in-license or acquire promising assets. This strategy, initiated in 2018 with assets from Shire, relies on their proven operational team to develop and maximize the value of external innovations.
Mirum views the retreat of large pharmaceutical companies from the rare disease space as a strategic opportunity. This creates a less competitive environment for acquisitions, allowing Mirum to acquire assets that are often overlooked by larger players and serve patient populations others leave behind.
In its acquisition of Bluejay, Mirum employed a creative deal structure combining stock and cash. The stock component ensures Bluejay's shareholders remain invested in the asset's success, while sales milestones de-risk the acquisition for Mirum and allow the selling team to share in future upside, creating a win-win partnership.
Mirum's acquisition strategy targets late-stage assets like berlovitug that can leverage its established global commercial operations. This approach maximizes efficiency, as new products fit into the existing sales structure supporting its current portfolio, especially in the adult hepatology space, making the acquisition highly strategic.
While known for late-stage acquisitions, Mirum strategically uses smaller deals for early-stage assets to expand its capabilities. The Anthoran Therapeutics deal serves as a model: a low upfront payment with a back-ended structure allows Mirum to enter early-phase development—a new area for the company—while managing financial risk.